Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, announces the successful achievement of a discovery research milestone under its exclusive research collaboration and licence agreement with Merck. In conjunction with the milestone achievement, Amphista receives a pre-specified financial payment. The associated target on which the milestone is triggered is currently undisclosed.

“As we continue to build our portfolio of first- and/or best-in-class Targeted Glues™, we are delighted to have reached an important milestone in our collaboration with Merck. The progress we have made together speaks to the effective partnership between scientists from both companies, enabling us to focus on advancing high-quality compounds for further development,” said Antony Mattessich, Chief Executive Officer at Amphista. “This achievement reinforces the exceptional capabilities of our Eclipsys® platform in the rational design of orally bioavailable protein degraders, bringing us a step closer to improving patient outcomes.”

Under the agreement, Amphista is responsible for the discovery and early development of small molecule protein degraders using its Eclipsys® platform. Merck is granted a global exclusive license to the resulting degrader molecules and will be responsible for further development and commercialisation activities.